Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 29;21(1):107.
doi: 10.1186/s13075-019-1878-y.

High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus

Vilija Oke  1 , Iva Gunnarsson  2 , Jessica Dorschner  3 , Susanna Eketjäll  4 , Agneta Zickert  2 , Timothy B Niewold  3   5 , Elisabet Svenungsson  2
Affiliations

High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus

Vilija Oke et al. Arthritis Res Ther. .

Abstract

Background and aim: Interferons (IFNs) are considered to be key molecules in the pathogenesis of systemic lupus erythematosus (SLE). We measured levels of type I, II and III IFNs in a large cohort of patients with systemic lupus erythematosus (SLE) and controls and explored associations among high levels of different IFN types and distinct SLE features.

Methods: Four hundred ninety-seven well-characterized SLE patients and 322 population controls were included. Disease activity was assessed by SLE Disease Activity Index (SLEDAI) and Systemic Lupus Activity Measure (SLAM). Functional type I IFN activity was estimated by a WISH reporter cell assay. Levels of IFN-γ were estimated by MSD 30-plex assay. IFN-α and IFN-λ1 were measured by ELISA. Values above the third quartile of patients' measurements were defined as high. Associations among high IFN results and SLE features were investigated by nominal regression analysis.

Results: All IFN measurements were higher in SLE patients than in controls. High type I IFN activity correlated with levels of IFN-γ and IFN-α and associated with active SLE in most domains: weight loss, fatigue, fever, rash, lymphadenopathy, arthritis, nephritis and haematological manifestations. Specific SLE subsets were linked to the upregulation of different subtypes of circulating IFNs: high IFN-γ to arthritis, nephritis and anti-Ro60 antibodies and high IFN-α to mucocutaneous engagement and anti-Ro52 and anti-La antibodies. Isolated high IFN-λ1 was coupled to anti-nucleosome antibodies and less severe SLE.

Conclusions: High functional type I IFN activity captures active SLE in most domains, but more distinct patterns of organ involvement are associated with profiles of circulating IFNs. High IFN-γ as well as high functional type I IFN activity is a characteristic of severe SLE with nephritis and arthritis, while elevated levels of IFN-α associate with active mucocutaneous inflammation and a more benign cardiovascular profile. IFN-λ1 in isolation is associated with milder disease. Our findings suggest that IFNs contribute to the heterogeneity of clinical manifestations in SLE, and measuring circulating IFNs could assist in designing clinical trials with therapies targeting IFN pathways.

Keywords: Autoantibodies; Disease activity; Interferons; SLE.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The study was approved by Regional Ethical Review Board, Stockholm, Sweden. All participants gave informed written consent. The study was performed in accordance with Declaration of Helsinki.

Consent for publication

Not applicable

Competing interests

SE is an employee at Astra Zeneca. The other authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Type I IFN activity and levels of IFN-α, IFN-γ and IFN-λ1 in SLE patients and population controls. Type I IFN activity in vitro (a) and IFN-γ levels (b), IFN-α (c) and IFN-λ1 (d) were all higher in SLE patients then population controls (Mann-Whitney U test). The dashed boxes indicate individuals with high levels (> 75th percentile of patient measures) of each investigated IFN
Fig. 2
Fig. 2
The distribution of the proportions of patients with high levels of each IFN measurement. The Venn diagram depicts how patient groups with high levels of different IFNs distribute and overlap in the cohort (a), and among those with active SLE as scored by SLAM (b) and SLEDAI (c). Only patients in whom all four measurements were available are included in the analysis (n = 248). The number outside diagram indicates the number of patients who had none of the IFNs expressed at a high level (> 75th percentile of patient measures)
Fig. 3
Fig. 3
Distribution of IFN-high subsets among SLE patients with different characteristics. The figure illustrates how subsets of different IFN types distribute among patients with active SLE manifestations (a), past manifestations and events (b), positivity for autoantibodies (c) and laboratory parameters (d) (presented in %) as assessed at inclusion. Abbreviations: LN lupus nephritis, NPSLE neuropsychiatric SLE (*at inclusion, NPSLE was classified by 1982 ACR criteria, seizures or psychosis), aCL anti-cardiolipin, B2GP1 β2glycoprotein-I, LA lupus anticoagulant, ESR erythrocyte sedimentation rate, WBC white blood cells, PLT platelets. Only patients in whom all four measurements were available are included in the analysis (n = 248)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus. 2000;9:664–671. doi: 10.1191/096120300674499064. - DOI - PubMed
    1. Weckerle CE, Franek BS, Kelly JA, et al. Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 2011;63:1044–1053. doi: 10.1002/art.30187. - DOI - PMC - PubMed
    1. Rönnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med. 1991;115:178–183. doi: 10.7326/0003-4819-115-3-178. - DOI - PubMed
    1. Machold KP, Smolen JS. Interferon-gamma induced exacerbation of systemic lupus erythematosus. J Rheumatol. 1990;17:831–832. - PubMed
    1. Teruel M, Alarcón-Riquelme ME. The genetic basis of systemic lupus erythematosus: what are the risk factors and what have we learned. J Autoimmun. 2016;74:161–175. doi: 10.1016/j.jaut.2016.08.001. - DOI - PubMed

Publication types